F45.32 K58
Conditions
Interventions
Group 1: Treatment group A: Optimal personalized therapy
Continuation of ongoing treatment with additional optimal personalized therapy. Depending on and according to the psycho-somatic profile of t
Sponsors
Universitätsklinikum Heidelberg, Abteilung für Allgemeine Innere Medizin und Psychosomatik
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: * Irritable bowel syndrome according to ROM-IV criteria, * Irritable bowel syndrome in clinical assessment, * Patients who agree to participate in the study for at least 5 months, * Written informed consent
Exclusion criteria
Exclusion criteria: * Severe psychopathology preventing group therapy (e.g. acute schizophrenic disorder, acute suicidality, current substance dependence (alcohol/drugs)). * Psychopathology preventing short-term EMDR treatment (e.g. severe dissociative symptoms (DES-II >25%), complex post-traumatic stress disorder). * Severe comorbid organic disorder preventing participation (e.g. palliative terminal cancer, serious nephrological, hepatic, cardiovascular or neurological disease). *Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility of the study at the end of treatment The feasibility criterion is considered to be met if a sufficient number of patients agree to participate in the study and if 70% of the original participants remain part of the study until its conclusion. | — |
Secondary
| Measure | Time frame |
|---|---|
| An insight in the effectiveness of optimized personalized therapy will be gained according to the following: • Simultaneous and time-depended relationships between somatic and psychological parameters during the study and at follow-up, measured according to entries in online diaries. • Reduction of symptom severity and illness anxiety measured by IBS-SSS (irritable bowel syndrome severity scoring system) and WI-7 (whiteley index 7) in pre-post comparison and at follow-up. • Improvement in quality of life, measured according to the FDD-Qol (Functional Digestive Disorders Quality of Life) in pre-post comparison and at follow-up. • Reduction in anxiety and depression-related symptoms, measured according to the PHQ-9 (Patient Health Questionnaire 9) and the GAD-7 (Generalized Anxiety Disorder 7) in pre-post comparison and at follow-up. • Change in somatic parameters (microbiome, heart rate variability, pain threshold) in pre-post comparison and at follow-up. | — |
Countries
Germany
Contacts
Public ContactFelicitas Engel
Universitätsklinikum Heidelberg, Abteilung für Allgemeine Innere Medizin und Psychosomatik
Outcome results
None listed